61 results
Page 2 of 4
8-K
EX-99.1
9w3 xixa0ory1s39txpt
10 Aug 20
Recro Reports Second Quarter 2020 Financial Results
7:06am
8-K
EX-2.1
ygtqhb9l9a8cyxf3gtv3
26 Nov 19
Entry into a Material Definitive Agreement
4:54pm
8-K
EX-99.1
fj53xk9 u8i
5 Nov 19
Recro Pharma’s Board of Directors Approves Separation of Acute
7:07am
8-K
EX-99.1
6tvpmk9h25y0 lprs
5 Apr 19
Cost Associated with Exit or Disposal Activities
4:01pm
8-K
EX-99.1
35l ti2nz4q9evfgz
28 Mar 19
Recro Pharma Appoints Arnaud Ajdler to Its Board of Directors
6:05am
8-K
EX-99.1
udh1ozjs6h1xy
22 Mar 19
Recro Pharma Receives Complete Response Letter from the FDA for Intravenous Meloxicam
4:17pm
424B5
e5kdec78l076qkc9 ord
19 Feb 19
Prospectus supplement for primary offering
8:39am
8-K
EX-99.1
trwi vx9eydf336wepya
19 Feb 19
Recro Pharma Reports Financial Results for the Fourth Quarter and Year End 2018
7:05am
8-K
EX-99.1
dmcanp
10 Dec 18
Other Events
2:07pm
8-K
EX-99.1
7x0los7 quvv7efrncl
7 Nov 18
Recro Pharma Reports Third Quarter 2018 Financial Results
7:06am
8-K
EX-99.1
zjin0l979 58c1
9 Oct 18
Recro Pharma Announces PDUFA Date for IV Meloxicam
6:07am